Baf57 is a potential determinant of colorectal cancer malignancy

HIROFUMI SUZUMURA, MASASHI TSURUTA, KOJI OKABAYASHI, KOHEI SHIGETA, RYO SEISHIMA, TAKASHI ISHIDA, TAKEHIRO SHIMADA, YUSUKE ASADA, KAORU KOISHIKAWA, SHINGO AKIMOTO, OSAMU ITANO, HIROTOSHI HASEGAWA, YUKO KITAGAWA

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: The role of brahma-related gene 1 (BRG1)-associated factor 57 (BAF57), a transcription factor, has been determined in prostate, breast, and ovarian cancer. However, the relationship between BAF57 and colorectal cancer (CRC) is obscure. Thus, we examined the functional correlation between BAF57 expression and oncological malignancy in CRC in vitro. Materials and Methods: BAF57 expression in WiDr and HT29 CRC cell lines and clinical specimens from CRC patients was analysed by western blotting and/or RT-PCR. BAF57 expression was down-regulated in WiDr cells through siRNA transfection. An invasion assay was also performed to assess malignancy. Results: BAF57 was expressed in both human CRC cell lines. Overall survival and recurrence-free survival rates were significantly reduced in high BAF57-expressing specimens. BAF57 expression was an independent predictive factor for long-term survival. Conclusion: BAF57 correlates with oncological malignancy and may be a novel therapeutic target in CRC.

Original languageEnglish
Pages (from-to)5445-5452
Number of pages8
JournalAnticancer research
Volume41
Issue number11
DOIs
Publication statusPublished - 2021 Nov

Keywords

  • BAF57
  • Colorectal cancer
  • Prognostic factor
  • Therapeutic target
  • Transcription factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Baf57 is a potential determinant of colorectal cancer malignancy'. Together they form a unique fingerprint.

Cite this